Drugs / P1G10
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03700580 | Aug 2012 → Oct 2016 | diabetic neuropathy, ulcer of lower limbs | Carlos E Salas | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P1G10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03700580 ↗ |
| Known as | proteolytic fraction from Vasconcellea cundinamarcensis | “The aim of the study was to investigate the role of the proteolytic fraction from Vasconcellea cundinamarcensis, designated as P1G10, on the healing of chronic foot ulcers in...” PMID 29564750 ↗ Mar 2018 |
| Route | Topical | “topical dressing formulated with 0.1% P1G10” PMID 29564750 ↗ Mar 2018 |